Results from the BIONYX Trial found the Resolute Onyx stent provided better x-ray visibility compared to Orsiro, an established cobalt-chromium strut stent, according to findings presented Monday, Sept. 24, at the Transcatheter Cardiovascular Therapeutics (TCT) symposium in San Diego.